Payment overview · 2025
General Payments
$277.19
14 reported records · 5 companies
Healthcare provider profile · identity verified
Leanne Wiley Rawlings, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EMPORIA, VA · NPI 1952533432
Verified facts
What the public records show
CMS Open Payments records show Leanne Wiley Rawlings, FNP received $277.19 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.97 | 33.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.59 | 30.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.74 | 19.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.86 | 10.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.03 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.19 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.74 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.27 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.25 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 630 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 101 |
| Gabapentin | Gabapentin | 275 | 54 |
| Furosemide | Furosemide | 260 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 55 |
| Metformin Hcl | Metformin Hcl | 244 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 232 | 49 |
| Montelukast Sodium | Montelukast Sodium | 217 | 50 |
| Omeprazole | Omeprazole | 212 | 54 |
| Prednisone | Prednisone | 189 | 115 |
| Lisinopril | Lisinopril | 181 | 33 |
| Potassium Chloride | Potassium Chloride | 171 | 36 |
| Losartan Potassium | Losartan Potassium | 165 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 36 |
| Glipizide | Glipizide | 151 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 30 |
| Meloxicam | Meloxicam | 133 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 24 |
| Eliquis | Apixaban | 112 | 20 |
| Lorazepam | Lorazepam | 109 | 15 |
| Alprazolam | Alprazolam | 105 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 100 | 19 |
| Trazodone Hcl | Trazodone Hcl | 92 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 22 |
| Azithromycin | Azithromycin | 86 | 64 |
| Carvedilol | Carvedilol | 86 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 16 |
| Buspirone Hcl | Buspirone Hcl | 80 | 14 |
| Famotidine | Famotidine | 79 | 15 |
| Simvastatin | Simvastatin | 79 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 78 | 20 |
| Meclizine Hcl | Meclizine Hcl | 78 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 12 |
| Amoxicillin | Amoxicillin | 73 | 55 |
| Sertraline Hcl | Sertraline Hcl | 73 | 13 |
| Donepezil Hcl | Donepezil Hcl | 72 | 13 |
| Tramadol Hcl | Tramadol Hcl | 72 | 28 |
| Colchicine | Colchicine | 71 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 59 | 44 |
| Farxiga | Dapagliflozin Propanediol | 57 | 11 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 11 |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Ondansetron Odt | Ondansetron | 52 | 16 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | suppressed |
| Indomethacin | Indomethacin | 50 | 16 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 13 |
| Naproxen | Naproxen | 48 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Topiramate | Topiramate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Ibu | Ibuprofen | 37 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 22 |
| Ozempic | Semaglutide | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Lactulose | Lactulose | 25 | 12 |
| Valsartan | Valsartan | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Clotrimazole | Clotrimazole | 23 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 11 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Torsemide | Torsemide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.19 · 14 records | ABBVIE INC. | ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error